{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-24-000033","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2024-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.611203+00:00","generated_at":"2026-06-03T21:48:46.860225+00:00","sec_items":["1.01","2.03","5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AEON Biopharma issues $10M convertible note to Daewoong, appoints Daewoong CEO to board","bullets":["Issued $10M senior secured convertible note to Daewoong on April 12, 2024, with 15.79% annual interest and maturity April 12, 2027.","Proceeds will support late-stage clinical development of ABP-450 and general working capital.","Appointed Seongsoo Park (CEO of Daewoong) as Class III director, expanding board from five to six members.","Note is identical in terms to the $5M convertible note issued March 24, 2024 under the same subscription agreement.","Mr. Park will serve until the 2026 annual meeting; he brings industry and leadership experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-24-000033","json":"https://secwatch.observer/filing/0001837607-24-000033.json","markdown":"https://secwatch.observer/filing/0001837607-24-000033.md","text":"https://secwatch.observer/filing/0001837607-24-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/0001837607-24-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/aeon-20240412x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T21:48:46.860225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1d9160937abeeb81bfdb3570d1459f02677b2bab","claim":"AEON Biopharma, Inc. incurred convertible notes of $10.0 million with Daewoong Pharmaceutical Co., LTD. at annual rate of 15.79% maturing April 12, 2027.","evidence_excerpt":"on April 12, 2024, AEON issued and sold to Daewoong one senior secured convertible note (the “Convertible Note”) in the principal amount of $10.0 million","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/0001837607-24-000033-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$10.0 million"},{"label":"Counterparty","value":"Daewoong Pharmaceutical Co., LTD."},{"label":"Rate","value":"annual rate of 15.79%"},{"label":"Maturity","value":"April 12, 2027"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"ea1e01dc74","claim":"Seongsoo Park was appointed as Class III director at AEON Biopharma, Inc..","evidence_excerpt":"the Board of Directors (the “Board”) of the Company appointed Seongsoo Park as a Class III director of the Board, effective as of April 12, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/0001837607-24-000033-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"},{"claim_id":"360f8bda9a9d2ca95519d928f0358ba7244148b9","claim":"AEON Biopharma, Inc. entered into Convertible Note with Daewoong Pharmaceutical Co., LTD. valued at $10.0 million (effective 2024-04-12).","evidence_excerpt":"on April 12, 2024, AEON issued and sold to Daewoong one senior secured convertible note (the “Convertible Note”) in the principal amount of $10.0 million.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760724000033/0001837607-24-000033-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"Daewoong Pharmaceutical Co., LTD."},{"label":"Value","value":"$10.0 million"},{"label":"Effective","value":"2024-04-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}